AN2 Therapeutics
ANTX
31 hedge funds and large institutions have $14.5M invested in AN2 Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 22 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
19.8% less ownership
Funds ownership: 65.09% → 45.29% (-20%)
31% less funds holding
Funds holding: 45 → 31 (-14)
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
65% less capital invested
Capital invested by funds: $41.7M → $14.5M (-$27.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$9.98M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$774K |
| 3 |
Renaissance Technologies
New York
|
+$711K |
| 4 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$174K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$6.92M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.16M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$4.49M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.34M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2.61M |
ANTX Hedge Fund Activity: Q3 2024 in Review
31 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2024, worth a combined $14.5M — down 65% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANTX and 8 opened new positions — a net loss of 14 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $9.98M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $6.92M sold.
- 31 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2024, down from 45 in Q2 2024.
- Funds reported $14.5M of AN2 Therapeutics stock for Q3 2024, down 65% quarter-over-quarter.
- 8 funds opened new AN2 Therapeutics positions in Q3 2024 and 22 closed out, a net change of -14 holders.
- The largest AN2 Therapeutics buyer in Q3 2024 was BML Capital Management, an estimated $9.98M added.
- The largest AN2 Therapeutics seller in Q3 2024 was Octagon Capital Advisors, an estimated $6.92M sold.
Based on aggregated 13F filings for Q3 2024.